首页> 外文期刊>Journal of the American Society of Hypertension : >MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage
【24h】

MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage

机译:原发性高血压患者MicroRNA-9和microRNA-126的表达水平:靶器官损伤的潜在标志

获取原文
获取原文并翻译 | 示例
           

摘要

MicroRNAs (miRs), as essential gene expression regulators, modulate cardiovascular development and disease and thus they are emerging as potential biomarkers and therapeutic targets in cardiovascular disease, including hypertension. We assessed the expression levels of the microRNAs miR-9 and miR-126 in 60 patients with untreated essential hypertension and 29 healthy individuals. All patients underwent two-dimensional echocardiography and 24-hour ambulatory blood pressure monitoring. MicroRNA expression levels in peripheral blood mononuclear cells were quantified by real-time reverse transcription polymerase chain reaction. Hypertensive patients showed significantly lower miR-9 (9.69 +/- 1.56 vs 41.08 +/- 6.06; P < .001) and miR-126 (3.88 +/- 0.47 vs 8.96 +/- 1.69; P < .001) expression levels compared with healthy controls. In hypertensive patients, miR-9 expression levels showed a significant positive correlation (r = 0.437; P < .001) with left ventricular mass index. Furthermore, both miR-9 (r = 0.312; P = .015) and miR-126 (r = 0.441; P < .001) expression levels in hypertensive patients showed significant positive correlations with the 24-hour mean pulse pressure. Our data reveal that miR-9 and miR-126 are closely related to essential hypertension in humans, as they show a distinct expression profile in hypertensive patients relative to healthy individuals, and they are associated with clinical prognostic indices of hypertensive target-organ damage in hypertensive patients. Thus, they may possibly represent potential biomarkers and candidate therapeutic targets in essential hypertension. (C) 2014 American Society of Hypertension. All rights reserved.
机译:MicroRNA(miR)作为必需的基因表达调节剂,可调节心血管的发育和疾病,因此它们正在成为包括高血压在内的心血管疾病的潜在生物标志物和治疗靶标。我们评估了60例未经治疗的原发性高血压患者和29例健康个体中microRNA miR-9和miR-126的表达水平。所有患者均进行了二维超声心动图检查和24小时动态血压监测。通过实时逆转录聚合酶链反应定量外周血单核细胞中的MicroRNA表达水平。高血压患者的miR-9(9.69 +/- 1.56 vs 41.08 +/- 6.06; P <.001)和miR-126(3.88 +/- 0.47 vs 8.96 +/- 1.69; P <.001)表达水平显着降低与健康对照相比。在高血压患者中,miR-9表达水平与左心室质量指数呈显着正相关(r = 0.437; P <.001)。此外,高血压患者的miR-9(r = 0.312; P = .015)和miR-126(r = 0.441; P <.001)表达水平均与24小时平均脉压显着正相关。我们的数据显示,miR-9和miR-126与人类原发性高血压密切相关,因为它们在高血压患者中相对于健康个体显示出独特的表达特征,并且与高血压靶器官损害的临床预后指标相关。高血压患者。因此,它们可能代表原发性高血压的潜在生物标志物和候选治疗靶标。 (C)2014年美国高血压学会。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号